[go: up one dir, main page]

LU90987I2 - Copaxone et ses dérivés pharmaceutiquement acceptables - Google Patents

Copaxone et ses dérivés pharmaceutiquement acceptables

Info

Publication number
LU90987I2
LU90987I2 LU90987C LU90987C LU90987I2 LU 90987 I2 LU90987 I2 LU 90987I2 LU 90987 C LU90987 C LU 90987C LU 90987 C LU90987 C LU 90987C LU 90987 I2 LU90987 I2 LU 90987I2
Authority
LU
Luxembourg
Prior art keywords
copaxone
pharmaceutically acceptable
acceptable derivatives
copolymer
kilodaltons
Prior art date
Application number
LU90987C
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90987(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of LU90987I2 publication Critical patent/LU90987I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyamides (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
LU90987C 1994-05-24 2002-08-05 Copaxone et ses dérivés pharmaceutiquement acceptables LU90987I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US34424894A 1994-11-23 1994-11-23
PCT/US1995/006551 WO1995031990A1 (fr) 1994-05-24 1995-05-23 Ameliorations apportees a des compositions de copolymeres contenant du copolymere-1

Publications (1)

Publication Number Publication Date
LU90987I2 true LU90987I2 (fr) 2003-02-25

Family

ID=26939072

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90987C LU90987I2 (fr) 1994-05-24 2002-08-05 Copaxone et ses dérivés pharmaceutiquement acceptables

Country Status (30)

Country Link
US (11) US5800808A (fr)
EP (1) EP0762888B1 (fr)
JP (2) JPH10500955A (fr)
KR (1) KR100403750B1 (fr)
CN (2) CN1310673C (fr)
AT (1) ATE212857T1 (fr)
AU (1) AU2602195A (fr)
BR (2) BR9507758A (fr)
CA (1) CA2191088C (fr)
CZ (1) CZ292247B6 (fr)
DE (2) DE10299030I1 (fr)
DK (1) DK0762888T3 (fr)
EE (1) EE03423B1 (fr)
ES (1) ES2172586T3 (fr)
FI (1) FI120236B (fr)
GE (1) GEP20002205B (fr)
HU (1) HU223473B1 (fr)
IL (2) IL113812A (fr)
LU (1) LU90987I2 (fr)
MD (1) MD1443G2 (fr)
NL (1) NL300096I2 (fr)
NO (1) NO324528B1 (fr)
NZ (1) NZ287335A (fr)
PL (1) PL181026B1 (fr)
PT (1) PT762888E (fr)
SI (1) SI0762888T1 (fr)
SK (1) SK283699B6 (fr)
TJ (1) TJ392B (fr)
UA (1) UA62908C2 (fr)
WO (1) WO1995031990A1 (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
HUP0100891A2 (hu) * 1998-02-13 2001-06-28 Autoimmune, Inc. A COP-1 és Th2 fokozó citokinek gyógyászati alkalmazása
EP1105414A2 (fr) 1998-07-23 2001-06-13 President And Fellows of Harvard College Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2337688C (fr) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Traitement de maladies auto-immunes a l'aide du copolymere 1 et copolymeres associes
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
JP4629229B2 (ja) 1998-09-25 2011-02-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 分子量マーカーとして用いるため、また治療用途のための共重合体１関連ポリペプチド
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (fr) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Administration en jours alternes de copolymer 1 destine au traitement de maladies autoimmunes
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
ES2243450T3 (es) * 2000-01-20 2005-12-01 Yeda Research And Development Co. Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
WO2005046719A1 (fr) 2003-11-12 2005-05-26 Yeda Research And Development Co. Ltd. Vaccin et procede pour traiter des maladies neurodegeneratives
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
AU3846901A (en) * 2000-02-18 2001-08-27 Yeda Res & Dev Oral, nasal and pulmonary dosage formualtions of copolymer 1
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL153236A0 (en) * 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
MXPA02007109A (es) * 2000-06-07 2002-12-13 Yeda Res & Dev El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para proteger a las celulas del sistema nervioso central de la toxicidad del glutamato.
AU6887101A (en) * 2000-06-20 2002-01-02 Caprion Pharmaceuticals, Inc. Copolymers and methods of treating prion-related diseases
WO2002076503A1 (fr) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
IL137460A0 (en) 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
KR100442122B1 (ko) * 2001-07-31 2004-07-30 한국전기연구원 영구 자석을 이용한 브러시리스 발전기
JP4369234B2 (ja) * 2001-12-04 2009-11-18 テバ ファーマシューティカル インダストリーズ リミティド グラチラマー・アセテートの強度の測定のための方法
CN102151330B (zh) * 2001-12-06 2017-04-12 耶达研究及发展有限公司 治疗运动神经元疾病的疫苗和方法
WO2003059387A2 (fr) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Polytherapie pour la sclerose en plaques
CA2411786C (fr) 2002-11-13 2009-01-27 Brantford Chemicals Inc. Methode de preparation de polypeptide 1
ATE548045T1 (de) 2003-01-07 2012-03-15 Yeda Res & Dev Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung
PT1592384E (pt) * 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
EP1603530A1 (fr) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Traitement combine a base d'acetate de glatiramer et d'alphacalcidol, destine au traitement de la sclerose en plaques
AU2004227852B2 (en) 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
EP1680087A1 (fr) * 2003-10-31 2006-07-19 Teva Pharmaceutical Industries Limited Nanoparticules pour la delivrance de medicaments
EP1701730B1 (fr) 2003-12-09 2013-08-21 Yeda Research And Development Co., Ltd. Methode et vaccin comprenant le copolymere 1 pour le traitement de troubles psychiatriques
CA2556152A1 (fr) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Melanges de peptides a activite immunomodulatrice
WO2005085323A2 (fr) * 2004-03-01 2005-09-15 Peptimmune, Inc. Methodes et compositions pour traiter des maladies auto-immunes
WO2005084377A2 (fr) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Therapie de combinaison avec acetate de glatiramer et riluzole
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
WO2005120542A2 (fr) 2004-05-07 2005-12-22 Peptimmune, Inc. Methodes de traitement de maladie a l'aide de copolymeres aleatoires
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060229233A1 (en) 2004-06-25 2006-10-12 Id Biomedical Corporation Compositions and methods for treating neurological disorders
DK1797109T3 (en) * 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US7495072B2 (en) * 2004-09-09 2009-02-24 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
CA2583589C (fr) * 2004-10-29 2012-04-24 Sandoz Ag Procedes de preparation d'un glatiramere
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
CA2588908C (fr) * 2004-11-29 2014-09-23 Yeda Research And Development Co. Ltd Induction de neurogenese et therapie par cellules souches en combinaison avec le copolymere 1
ZA200705874B (en) * 2005-02-02 2009-04-29 Teva Pharma Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
WO2006116602A2 (fr) * 2005-04-25 2006-11-02 Yeda Research And Development Company Marqueurs associes a l'efficacite therapeutique d'acetate de glatiramere
WO2007081975A2 (fr) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Méthode de traitement de la sclérose en plaques
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
AU2007238595A1 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
EP2013628B1 (fr) * 2006-04-28 2016-01-06 Momenta Pharmaceuticals, Inc. Procédés d'évaluation de mélanges peptidiques
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
EP2046366B1 (fr) 2006-06-28 2016-08-31 Yeda Research And Development Company Limited Copolymer-1 pour le traitement de la dégénérescence maculaire liée à l'âge
DE602007003848D1 (de) * 2006-07-05 2010-01-28 Momenta Pharmaceuticals Inc Verbessertes verfahren zur herstellung von copolymer-1
EP2381254B2 (fr) 2007-06-21 2017-07-19 Momenta Pharmaceuticals, Inc. Analyse de copolymères
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
EP2173766A1 (fr) * 2007-07-31 2010-04-14 Natco Pharma Limited Procédé de préparation de l'acétate de glatiramer (copolymère-1)
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
EP2217250A4 (fr) 2007-11-09 2011-01-05 California Inst Of Techn Composés immunorégulateurs et compositions et procédés apparentés
BRPI0819001A2 (pt) * 2007-11-28 2014-10-07 Teva Pharma "método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer
EP2277050B2 (fr) * 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analyse de compositions copolymères d'acides aminés
US8399600B2 (en) * 2008-08-07 2013-03-19 Sigma-Aldrich Co. Llc Preparation of low molecular weight polylysine and polyornithine in high yield
AU2009279636A1 (en) * 2008-08-07 2010-02-11 Scinopharm Taiwan, Ltd. Synthesis of glatiramer acetate
AR074881A1 (es) 2008-12-24 2011-02-16 Synthon Bv Un proceso para purificar una mezcla de polimeros
RU2011144566A (ru) * 2009-04-03 2013-05-10 Момента Фармасьютикалз, Инк. Контроль сополимерных композиций
AU2009347384B2 (en) 2009-06-04 2014-10-23 Council Of Scientific & Industrial Research A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
ES2383347T3 (es) * 2009-07-15 2012-06-20 Teva Pharmaceutical Industries, Ltd. Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
EP2405749B1 (fr) 2009-08-20 2013-05-08 Yeda Research and Development Co., Ltd. Thérapie à l'acétate de glatiramère à basse fréquence
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
HRP20182076T1 (hr) 2010-01-04 2019-02-08 Mapi Pharma Limited Sustav s kontroliranim otpuštanjem koji obuhvaća glatiramer acetat
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20130035390A1 (en) 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
DK2555753T3 (en) 2010-04-07 2018-11-26 California Inst Of Techn Vesicle for delivering a compound to a mucosal membrane as well as corresponding compositions, methods and systems
RU2012150443A (ru) * 2010-04-27 2014-06-10 Др. Редди'С Лабораторис Лтд. Получение полипептидов и их солей
WO2011146910A1 (fr) 2010-05-20 2011-11-24 Round June L Treg spécifiques d'un antigène et compositions, procédés et systèmes associés
EP2598889A4 (fr) 2010-07-29 2014-01-22 Reddys Lab Ltd Dr Marqueurs de masse moléculaire à base d'acétate de glatiramer
BR112013008573A2 (pt) 2010-10-11 2016-07-12 Teva Pharma citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.
CA2827275A1 (fr) 2011-02-14 2012-09-20 Usv Limited Copolymere-1, son procede de preparation et methodes d'analyse de celui-ci
EP2699317B1 (fr) 2011-04-21 2016-08-10 Mapi Pharma Limited Pentapolymère statistique pour le traitement de maladies auto-immunes
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009864A1 (fr) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Évaluation de structure de mélanges polypeptidiques hétérogènes
WO2013009885A2 (fr) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation de diéthylamide de copolymère
EP2731617A4 (fr) 2011-07-12 2015-07-01 Brigham & Womens Hospital Compositions de psa contenant des lipides, procédés d'isolement et procédés pour les utiliser
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CN103957705A (zh) 2011-10-10 2014-07-30 泰华制药工业有限公司 适用于预测对醋酸格拉替雷的临床反应的单核苷酸多态性
EP2642290A1 (fr) 2012-03-19 2013-09-25 Synthon BV Analyse de la puissance de l'acétate de glatiramère basée sur des lignées de cellules monocytaires humaines
WO2013139728A1 (fr) 2012-03-19 2013-09-26 Synthon Bv Test d'activité biologique de l'acétate de glatiramère à base de cellules monocytaires humaines
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
WO2014060942A2 (fr) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions et méthodes pour le traitement de la sclérose en plaques et de maladies neurodégénératives
WO2014128079A1 (fr) 2013-02-19 2014-08-28 Synthon B.V. Formulation multidose d'acétate de glatiramère
RS53779B1 (sr) 2013-03-08 2015-06-30 Teva Pharmaceutical Industries Ltd. Injekcioni uređaj za višekratnu upotrebu za špric
DK2774639T3 (en) 2013-03-08 2015-01-12 Teva Pharma Reusable injection device for a syringe
EP2971173A4 (fr) 2013-03-14 2016-11-23 Mylan Inc Essai de puissance d'acétate de glatiramère par biomarqueurs de réponse arnm
WO2014173463A1 (fr) 2013-04-26 2014-10-30 Synthon Bv Test d'activité biologique basé sur les lignées cellulaires monocytaires humaines au moyen d'acétate de glatiramère
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
CN104371012A (zh) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2928084A1 (fr) 2013-10-24 2015-04-30 Mylan Inc. Dosage de lignee de cellules t humaines pour evaluer l'identite immunologique de preparations d'acetate de glatiramere
JP2017503169A (ja) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
BR112016020919A2 (pt) 2014-03-12 2018-01-23 Yeda Res & Dev redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2016201342A1 (fr) 2015-06-10 2016-12-15 California Institute Of Technology Traitement du sepsis, compositions, méthodes et systèmes associés
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
ES2744179T3 (es) 2015-09-24 2020-02-24 Chemi Spa Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
EP3170836B1 (fr) 2015-11-23 2018-10-24 Chemi SPA Analyse rp-hplc de mélanges de polypeptides complexes
CN107522774B (zh) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
WO2018002930A1 (fr) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Traitement d'une maladie intestinale inflammatoire avec du glatiramère à action prolongée et des cellules souches dérivées du tissu adipeux
EP3484441A4 (fr) 2016-07-15 2020-03-18 President and Fellows of Harvard College Compositions de glycolipide et procédés d'utilisation
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109689082A (zh) 2016-08-28 2019-04-26 Mapi医药公司 用于制备包含醋酸格拉替雷的微粒的方法
FI3506921T3 (fi) 2016-08-31 2023-07-21 Mapi Pharma Ltd Glatirameeriasetaattia käsittäviä depot-järjestelmiä
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
CA3062964C (fr) 2017-05-15 2024-11-12 Mapi Pharma Ltd. Traitement de la sclerose en plaques avec un glatiramere a action prolongee et des cellules souches derivees du tissu adipeux
AU2018270396B2 (en) 2017-05-15 2025-03-20 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
EP3765034A1 (fr) 2018-03-12 2021-01-20 Yeda Research and Development Co. Ltd Traitement d'une maladie cardiaque

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
DE3684333D1 (de) 1985-06-18 1992-04-16 Univ Emory Biologisch wirksame kopolymere.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (de) * 1989-01-13 1989-08-03 Indag Gesellschaft für Industriebedarf mbH, 69214 Eppelheim Folienbeutel
CA2009996A1 (fr) * 1989-02-17 1990-08-17 Kathleen S. Cook Procede de production de genes encodant des polymeres aleatoires d'acides amines
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
WO1993010231A1 (fr) * 1991-11-12 1993-05-27 E.I. Du Pont De Nemours And Company Polypeptides analogues au collagene
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2001524011A (ja) 1997-05-06 2001-11-27 クワンタ・ビジョン 組織分析装置
ES2243450T3 (es) * 2000-01-20 2005-12-01 Yeda Research And Development Co. Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora.
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Also Published As

Publication number Publication date
IL133890A0 (en) 2001-04-30
DE69525340D1 (de) 2002-03-21
PT762888E (pt) 2002-07-31
US20030064914A1 (en) 2003-04-03
EE03423B1 (et) 2001-06-15
CA2191088C (fr) 2004-09-28
NZ287335A (en) 1999-02-25
EE9600170A (et) 1997-06-16
US8367605B2 (en) 2013-02-05
IL113812A0 (en) 1995-08-31
IL113812A (en) 2000-06-29
HU9603243D0 (en) 1997-01-28
ES2172586T3 (es) 2002-10-01
NL300096I1 (nl) 2002-10-01
AU2602195A (en) 1995-12-18
NO324528B1 (no) 2007-11-12
SI0762888T1 (en) 2002-08-31
ATE212857T1 (de) 2002-02-15
HK1008657A1 (en) 1999-05-14
EP0762888A4 (fr) 1997-04-16
JP2003105000A (ja) 2003-04-09
BR9507758A (pt) 1997-09-23
GEP20002205B (en) 2000-08-25
KR100403750B1 (ko) 2006-02-13
MD1443F1 (en) 2000-04-30
US20050171286A1 (en) 2005-08-04
PL181026B1 (pl) 2001-05-31
WO1995031990A1 (fr) 1995-11-30
KR970703154A (ko) 1997-07-03
US6939539B2 (en) 2005-09-06
TJ392B (en) 2004-10-13
DE69525340T2 (de) 2002-09-19
US6620847B2 (en) 2003-09-16
SK149396A3 (en) 1997-08-06
CZ341096A3 (en) 1997-06-11
CN1152874A (zh) 1997-06-25
FI120236B (fi) 2009-08-14
FI964600A0 (fi) 1996-11-15
US6054430A (en) 2000-04-25
US5981589A (en) 1999-11-09
CN1310673C (zh) 2007-04-18
CZ292247B6 (cs) 2003-08-13
NL300096I2 (nl) 2003-02-03
HUT75672A (en) 1997-05-28
US20040106554A1 (en) 2004-06-03
CN1174753C (zh) 2004-11-10
DE10299030I1 (de) 2003-01-23
JP3715600B2 (ja) 2005-11-09
US20120077754A1 (en) 2012-03-29
US20070117757A1 (en) 2007-05-24
US6362161B1 (en) 2002-03-26
PL317331A1 (en) 1997-04-01
SK283699B6 (sk) 2003-12-02
UA62908C2 (uk) 2004-01-15
BRPI9507758B1 (pt) 2021-03-16
MD1443G2 (ro) 2000-11-30
CN1626238A (zh) 2005-06-15
FI964600L (fi) 1996-12-05
CA2191088A1 (fr) 1995-11-30
US6048898A (en) 2000-04-11
DK0762888T3 (da) 2002-05-27
NO964976D0 (no) 1996-11-22
US7625861B2 (en) 2009-12-01
NO964976L (no) 1997-01-23
JPH10500955A (ja) 1998-01-27
EP0762888B1 (fr) 2002-02-06
US7199098B2 (en) 2007-04-03
HU223473B1 (hu) 2004-07-28
US5800808A (en) 1998-09-01
US6342476B1 (en) 2002-01-29
EP0762888A1 (fr) 1997-03-19

Similar Documents

Publication Publication Date Title
LU90987I2 (fr) Copaxone et ses dérivés pharmaceutiquement acceptables
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
SE9504661D0 (sv) New compounds
DZ2043A1 (fr) Nouveaux dérivés.
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
ES2084149T3 (es) Conjugados de hirudinpolialquilenglicol.
NO980296D0 (no) Forbedrede terapeutiske midler
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
SE9504662D0 (sv) New compounds
CO4930269A1 (es) Composiciones farmaceuticas
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
FR2723372B1 (fr) Nouveaux derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2094930T3 (es) Nueva proteina inhibidora de trombina aislada de garrapatas.
MX9500324A (es) Compuestos farmaceuticos y el uso de los mismos en el tratamiento de enfermedades neurologicas y sus etiologias sintomaticas relacionadas.